The binding of polypeptide growth factors to their appropriate cell surface transmembrane receptors triggers numerous biochemical responses, including the transcriptional activation of specific genes. We have used a differential display approach to identify fibroblast growth factor-1-inducible genes in murine NIH 3T3 cells. Here, we report that the fibroblast growth factorinducible-14 (Fn14) gene is a growth factor-regulated, immediate-early response gene expressed in a developmental stage-and adult tissue-specific manner in vivo. This gene, located on mouse chromosome 17, is predicted to encode an 129-amino acid type Ia membrane protein with no significant sequence similarity to any known protein. We have used two experimental approaches, direct fluorescence microscopy and immunoprecipitation analysis of biotinylated cell surface proteins, to demonstrate that Fn14 is located on the plasma membrane. To examine the biological consequences of constitutive Fn14 expression, we isolated NIH 3T3 cell lines expressing variable levels of epitope-tagged Fn14 and analyzed their phenotypic properties in vitro. These experiments revealed that Fn14 expression decreased cellular adhesion to the extracellular matrix proteins fibronectin and vitronectin and also reduced serum-stimulated cell growth and migration. These results indicate that Fn14 is a novel plasma membrane-spanning molecule that may play a role in cell-matrix interactions.Complex cellular processes such as proliferation, migration, differentiation, and apoptosis are regulated in part by a diverse group of molecules known as polypeptide growth factors. These factors act by binding and thereby activating specific transmembrane receptor tyrosine kinases. The activation of cell surface receptors by polypeptide ligands triggers downstream intracellular events, including the stimulation of protein phosphorylation cascades and the transcriptional activation of numerous genes (1, 2). Many mitogen-inducible genes have been identified, and they encode a diverse group of proteins including transcription factors, protein kinases and phosphatases, cell cycle regulators, and cytoskeletal and extracellular matrix proteins (2, 3). A recent study using cDNA microarray technology has demonstrated that Ͼ500 genes are transcriptionally activated after serum stimulation of quiescent human fibroblasts and that a subset of these genes encode proteins implicated in the wound healing process in vivo (3).Our laboratory has been studying fibroblast growth factor-1 (FGF-1) 1 -regulated gene expression in murine NIH 3T3 cells. FGF-1 (also referred to as acidic FGF) is one of the most extensively characterized members of the FGF family of heparin-binding proteins (4 -6). It is a potent mitogenic, chemotactic, angiogenic, and neurotrophic factor both in vitro and in vivo. These cellular responses are mediated via high affinity binding to a family of related membrane-spanning tyrosine kinase receptors (4 -6). We have shown by Northern blot hybridization analysis that FGF-1 stimulation of quies...

Fibroblast growth factor (FGF)-1 mitogenic signal transduction is mediated in part by gene products that are specifically expressed in response to cell surface receptor binding and activation. We have used a targeted differential display method to identify FGF-1-inducible genes in murine NIH 3T3 fibroblasts. Here we report that one of these genes is predicted to encode a novel serine/threonine-specific protein kinase. This putative kinase has been named Fnk, for FGF-inducible kinase. The deduced Fnk amino acid sequence has 49, 36, 33, 32, and 22% overall identity to mouse serum-inducible kinase (Snk), mouse polo-like kinase (Plk), Drosophila polo, Saccharomyces Cdc5, and mouse Snk/Plk-akin kinase (Sak), respectively. These proteins are all members of the polo subfamily of structurally related serine/threonine kinases. The Plk, polo, Cdc5, and Sak kinases are required for cell division. FGF-1 induction of Fnk mRNA expression is first detected at 30 min after mitogen addition, reflects transcriptional activation, and does not require de novo protein synthesis. FGF-2, platelet-derived growth factor-BB, calf serum, or phorbol myristate acetate treatment of quiescent cells also induces fnk gene expression. Fnk mRNA is expressed in vivo in a tissue-specific manner, with relatively high levels detected in newborn and adult mouse skin. These results indicate that Fnk may be a transiently expressed protein kinase involved in the early signaling events required for growth factor-stimulated cell cycle progression.

Polo-like kinase 3 (Plk3) is an important mediator of the cellular responses to genotoxic stresses. In this study, we examined the physiologic function of Plk3 by generating Plk3-deficient mice. Plk3 À/À mice displayed an increase in weight and developed tumors in various organs at advanced age. Many tumors in Plk3 À/À mice were large in size, exhibiting enhanced angiogenesis. Plk3 À/À mouse embryonic fibroblasts were hypersensitive to the induction of hypoxiainducible factor-1A (HIF-1A) under hypoxic conditions or by nickel and cobalt ion treatments. Ectopic expression of the Plk3-kinase domain (Plk3-KD), but not its Polo-box domain or a Plk3-KD mutant, suppressed the nuclear accumulation of HIF-1A induced by nickel or cobalt ions. Moreover, hypoxiainduced HIF-1A expression was tightly associated with a significant down-regulation of Plk3 expression in HeLa cells. Given the importance of HIF-1A in mediating the activation of the ''survival machinery'' in cancer cells, these studies strongly suggest that enhanced tumorigenesis in Plk3-null mice is at least partially mediated by a deregulated HIF-1 pathway.

No abstract

Because fibroblast growth factors (FGFs) modulate important functions of endothelial cells (EC) and smooth muscle cells (SMC), we studied FGF expression in human vascular cells and control or atherosclerotic arteries. All cells and arteries contained acidic (a) FGF and basic (b) FGF mRNA. Northern analysis detected aFGF mRNA only in one of five control arteries but in all five atheroma tested, while levels of bFGF mRNA did not differ among control (n = 3) vs. plaque specimens (n = 6). Immunolocalization revealed abundant bFGF protein in control vessels (n = 10), but little in plaques (n = 14). In contrast, atheroma (n = 14), but not control arteries (n = 10), consistently exhibited immunoreactive aFGF, notably in neovascularized and macrophage-rich regions of plaque. Because macrophages colocalized with aFGF, we tested human monocytoid THP-1 cells and demonstrated accumulation of aFGF mRNA during PMA-induced differentiation. We also examined the expression of mRNA encoding FGF receptors (FGFRs). All cells and arteries contained FGFR-1 mRNA.Only SMC and control vessels had FGFR-2 mRNA, while EC and some arteries contained FGFR4 mRNA. The relative lack of bFGF in plaques vs. normal arteries suggests that this growth factor may not contribute to cell proliferation in advanced atherosclerosis. However, aFGF produced by plaque macrophages may stimulate the growth of microvessels during human atherogenesis. (J. Clin. Invest. 1993. 92:2408-2418